JP2021522786A5 - - Google Patents

Info

Publication number
JP2021522786A5
JP2021522786A5 JP2020560958A JP2020560958A JP2021522786A5 JP 2021522786 A5 JP2021522786 A5 JP 2021522786A5 JP 2020560958 A JP2020560958 A JP 2020560958A JP 2020560958 A JP2020560958 A JP 2020560958A JP 2021522786 A5 JP2021522786 A5 JP 2021522786A5
Authority
JP
Japan
Prior art keywords
fusion protein
structural unit
subunit
linker segment
protein according
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2020560958A
Other languages
English (en)
Japanese (ja)
Other versions
JP7684047B2 (ja
JP2021522786A (ja
Filing date
Publication date
Priority claimed from CN201810420739.6A external-priority patent/CN110437339B/zh
Application filed filed Critical
Publication of JP2021522786A publication Critical patent/JP2021522786A/ja
Publication of JP2021522786A5 publication Critical patent/JP2021522786A5/ja
Priority to JP2025082038A priority Critical patent/JP2025124695A/ja
Application granted granted Critical
Publication of JP7684047B2 publication Critical patent/JP7684047B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2020560958A 2018-05-04 2019-05-03 インターロイキン１５融合タンパク質、およびその組成物ならびに治療方法 Active JP7684047B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2025082038A JP2025124695A (ja) 2018-05-04 2025-05-15 インターロイキン１５融合タンパク質、およびその組成物ならびに治療方法

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN201810420739.6A CN110437339B (zh) 2018-05-04 2018-05-04 一种以白介素15为活性成分的融合蛋白型药物前体
CN201810420739.6 2018-05-04
PCT/US2019/030594 WO2019213517A1 (en) 2018-05-04 2019-05-03 Interleukin 15 fusion proteins, and compositions and therapeutic methods thereof

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2025082038A Division JP2025124695A (ja) 2018-05-04 2025-05-15 インターロイキン１５融合タンパク質、およびその組成物ならびに治療方法

Publications (3)

Publication Number Publication Date
JP2021522786A JP2021522786A (ja) 2021-09-02
JP2021522786A5 true JP2021522786A5 (enExample) 2022-05-13
JP7684047B2 JP7684047B2 (ja) 2025-05-27

Family

ID=68386875

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2020560958A Active JP7684047B2 (ja) 2018-05-04 2019-05-03 インターロイキン１５融合タンパク質、およびその組成物ならびに治療方法
JP2025082038A Pending JP2025124695A (ja) 2018-05-04 2025-05-15 インターロイキン１５融合タンパク質、およびその組成物ならびに治療方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2025082038A Pending JP2025124695A (ja) 2018-05-04 2025-05-15 インターロイキン１５融合タンパク質、およびその組成物ならびに治療方法

Country Status (8)

Country Link
US (1) US12441781B2 (enExample)
EP (1) EP3788068A4 (enExample)
JP (2) JP7684047B2 (enExample)
KR (1) KR20210028150A (enExample)
CN (4) CN110437339B (enExample)
AU (1) AU2019262590B2 (enExample)
CA (1) CA3099039A1 (enExample)
WO (1) WO2019213517A1 (enExample)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11629340B2 (en) 2017-03-03 2023-04-18 Obsidian Therapeutics, Inc. DHFR tunable protein regulation
CN109705211B (zh) 2017-10-26 2020-08-18 苏州复融生物技术有限公司 一种IgG1 Fc单体及其应用
CN111100211B (zh) * 2019-01-30 2022-04-08 武汉九州钰民医药科技有限公司 一种Fc融合蛋白及其应用
CN114651003A (zh) 2019-09-10 2022-06-21 黑曜石疗法公司 用于可调调节的ca2-il15融合蛋白
WO2021113577A1 (en) * 2019-12-05 2021-06-10 Immune Targeting Inc. Interleukin 15 fusion proteins and prodrugs, and compositions and methods thereof
CN113135996A (zh) * 2019-12-09 2021-07-20 启愈生物技术(上海)有限公司 一种双特异抗体及其应用
AU2020403148A1 (en) * 2019-12-13 2022-06-30 Cugene Inc. Cytokine-based bioactivatable drugs and methods of uses thereof
US12459984B2 (en) * 2019-12-27 2025-11-04 National University Corporation Kobe University Cancer gene therapy drug
WO2021142476A1 (en) * 2020-01-12 2021-07-15 Dragonfly Therapeutics, Inc. Single-chain polypeptides
CN113321738A (zh) * 2020-02-27 2021-08-31 启愈生物技术(上海)有限公司 肿瘤靶向、抗cd3和t细胞激活三功能融合蛋白及其应用
US20230141575A1 (en) * 2020-03-18 2023-05-11 City Of Hope Multivalent chemokine receptor binding complexes
US20230226203A1 (en) * 2020-06-18 2023-07-20 Proviva Therapeutics (Hong Kong) Limited Activatable procytokines
CN114057889B (zh) * 2020-07-30 2023-11-10 深圳市北科生物科技有限公司 二硫键稳定的IL15-IL15Rα复合物及其应用
EP4206219A1 (en) * 2020-08-31 2023-07-05 GI Cell, Inc. Fusion protein including il15 protein, il15 receptor alpha protein, fc domain, and il2 protein, and use thereof
KR20230104866A (ko) * 2020-09-16 2023-07-11 베이진 엘티디 인터류킨 15 작제물 및 사용 방법
CN118598977A (zh) * 2020-10-18 2024-09-06 北京志道生物科技有限公司 经修饰的il-2分子及其用途
US11459372B2 (en) 2020-11-30 2022-10-04 Crispr Therapeutics Ag Gene-edited natural killer cells
CN113321736B (zh) * 2020-12-30 2024-01-09 苏州复融生物技术有限公司 一种长效化白介素15融合蛋白及其制备方法和应用
EP4271798A1 (en) 2020-12-30 2023-11-08 CRISPR Therapeutics AG Compositions and methods for differentiating stem cells into nk cells
CA3214757A1 (en) * 2021-04-08 2022-10-13 Andreas Loew Multifuntional molecules binding to tcr and uses thereof
CN116375888A (zh) * 2021-05-08 2023-07-04 上海交通大学 一种融合蛋白及其制备方法和用途
CN113817072B (zh) * 2021-10-28 2024-02-20 苏州生物医药转化工程中心 一种白细胞介素15及其受体-单克隆抗体融合蛋白的纯化贮存方法
EP4435011A4 (en) * 2021-11-15 2025-07-16 Inst Biophysics Cas FUSION PROTEIN CONSTRUCTION TAKING INTERLEUKIN 15 AS ACTIVE INGREDIENT AND USE THEREOF
WO2023160721A1 (en) * 2022-02-28 2023-08-31 Wuxi Biologics (Shanghai) Co., Ltd. Heterodimeric polypeptide complexes comprising il-15 variants and uses thereof
WO2024039973A2 (en) * 2022-08-05 2024-02-22 Staidson Biopharma Inc. Masking polypeptide, activatable novel prodrugs and methods of use thereof
KR20250135294A (ko) * 2023-02-21 2025-09-12 레메젠 코, 리미티드 암을 위한 il-15 작용제
CN118909134A (zh) * 2023-05-06 2024-11-08 北京新合睿恩生物医疗科技有限公司 IL-15融合蛋白及其mRNA序列和应用
CN116554356B (zh) * 2023-05-16 2024-01-23 武汉大学 一种hyperIL-15与sCD4及Fc的融合蛋白及其应用
AU2023476910A1 (en) * 2023-12-19 2026-07-09 Immunelogic Therapeutics, Inc. Bifunctional fusion protein composed of il-15 and t cell co-stimulatory molecule antibody
WO2026006679A1 (en) * 2024-06-28 2026-01-02 The Regents Of The University Of California Retroviral vectors
WO2026037415A1 (zh) * 2024-08-16 2026-02-19 北京清辉联诺生物科技有限责任公司 一种IL15/IL15Rα复合物及其在细胞疗法领域的应用
WO2026042913A1 (ko) * 2024-08-22 2026-02-26 주식회사 박셀바이오 재조합 개 인터루킨-15를 포함하는 종양에 이환된 개의 암 치료용 조성물
US20260109746A1 (en) * 2024-10-22 2026-04-23 Gilead Sciences, Inc. Cd4-targeted il-15 molecules and methods of use
CN121949562A (zh) * 2024-10-30 2026-05-01 钱杭江医药科技(嘉兴)有限公司 一种新型蛋白复合物的二聚体化合物及其制备方法和制药用途
CN121422192A (zh) * 2025-11-20 2026-01-30 斯霈生物医药(北京)有限公司 一种序贯给药的细胞因子靶向治疗系统及其应用

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZA200704908B (en) * 2004-12-13 2008-10-29 Cytos Biotechnology Ag IL-15 Antigen Arrays and uses thereof
EP1777294A1 (en) * 2005-10-20 2007-04-25 Institut National De La Sante Et De La Recherche Medicale (Inserm) IL-15Ralpha sushi domain as a selective and potent enhancer of IL-15 action through IL-15Rbeta/gamma, and hyperagonist (IL15Ralpha sushi -IL15) fusion proteins
JP6251570B2 (ja) * 2010-09-21 2017-12-20 アルター・バイオサイエンス・コーポレーション 多量体ｉｌ−１５可溶性融合分子並びにその製造及び使用方法
EP2537933A1 (en) * 2011-06-24 2012-12-26 Institut National de la Santé et de la Recherche Médicale (INSERM) An IL-15 and IL-15Ralpha sushi domain based immunocytokines
EP2915569A1 (en) * 2014-03-03 2015-09-09 Cytune Pharma IL-15/IL-15Ralpha based conjugates purification method
US10905743B2 (en) * 2014-12-19 2021-02-02 Jiangsu Hengrui Medicine Co., Ltd. Interleukin 15 protein complex
CN112574316A (zh) * 2015-07-02 2021-03-30 博际生物医药科技(杭州)有限公司 用于肿瘤靶向治疗的白细胞介素-15融合蛋白
AU2016326575A1 (en) * 2015-09-25 2018-04-12 Altor Bioscience Corporation Interleukin-15 superagonist significantly enhances graft-versus-tumor activity
CA3001131A1 (en) * 2015-11-02 2017-05-11 Five Prime Therapeutics, Inc. Cd80 extracellular domain polypeptides and their use in cancer treatment
MX2019004327A (es) * 2016-10-14 2019-10-14 Xencor Inc Proteinas de fusion heterodimericas biespecificas que contienen proteinas de fusion fc il-15/il-15ra y fragmentos de anticuerpo pd-1.

Similar Documents

Publication Publication Date Title
JP2025032113A5 (enExample)
JP2021521822A5 (enExample)
EP3844181B1 (en) Multi-chain chimeric polypeptides and uses thereof
US12624088B2 (en) Chimeric receptor comprising a ligand binding domain and an endodomain comprising a cytokine receptor endodomain and an intracellular T cell signalling domain
EP3844182B1 (en) Single-chain and multi-chain chimeric polypeptides and uses thereof
Wilkie et al. Dual targeting of ErbB2 and MUC1 in breast cancer using chimeric antigen receptors engineered to provide complementary signaling
AU2020294797B2 (en) Multi-chain chimeric polypeptides and uses thereof
CN110724200B (zh) 嵌合细胞因子受体
JP2022169543A (ja) 改善された養子ｔ細胞療法
ES3018558T3 (es) Célula T que expresa un receptor de célula T gamma-delta (TCR) y un receptor de antígeno quimérico (CAR)
CN111527109A (zh) 以抗体Fc区为骨架的融合蛋白二聚体及其应用
JP2023503868A5 (enExample)
Karches et al. Bispecific antibodies enable synthetic agonistic receptor-transduced T cells for tumor immunotherapy
JP2026081255A (ja) インターロイキン２変異体およびその使用
Kermer et al. An antibody fusion protein for cancer immunotherapy mimicking IL-15 trans-presentation at the tumor site
WO2017000913A1 (zh) 用于肿瘤靶向治疗的白细胞介素15融合蛋白
WO2021032116A1 (zh) 一种免疫细胞因子及其制备与用途
JP2023551481A5 (enExample)
Lo et al. Regression of established renal cell carcinoma in nude mice using lentivirus-transduced human T cells expressing a human anti-CAIX chimeric antigen receptor
CN112601546A (zh) Plap-car-效应细胞
WO2024094119A1 (zh) 融合蛋白及其应用
CN110903402A (zh) 一种双特异性融合蛋白及其构建方法与应用
JP2023540022A5 (enExample)
JP2023540023A5 (enExample)
Burckhart et al. Tumor-specific crosslinking of GITR as costimulation for immunotherapy